106133-20-4
Chemical Structure
Tamsulosin
Synonym(s): (R)-(-)-YM12617 free base; LY253351 free base
- CAS No.: 106133-20-4
- Formula:C20H28N2O5S
- Molecular Weight:408.51
IUPAC Name: (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
InChIKey: DRHKJLXJIQTDTD-OAHLLOKOSA-N
SMILES: O=S(C1=CC(C[C@H](NCCOC2=CC=CC=C2OCC)C)=CC=C1OC)(N)=O
Biological Activity: Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α1-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tamsulosin | 99.80% | Tamsulosin ((R)-(-)-YM12617 free base) is an orally active antagonist of α1-adrenergic receptor. Tamsulosin induces Apoptosis. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tamsulosin (Standard) | ≥98% | Tamsulosin (Standard) is the analytical standard of Tamsulosin. This product is intended for research and analytical applications. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α1-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tamsulosin-d4 | Tamsulosin-d4 ((R)-(-)-YM12617 (free base)-d4) is deuterium labeled Tamsulosin. Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α1-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Christopher Chapple, et al. Tamsulosin: an overview. World J Urol. 2002 Apr;19(6):397-404. [Content Brief]
- [2]. Rak A, et al. Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α1-adrenergic receptor antagonist with uro-selective activity. Bioorg Med Chem. 2016 Nov 1;24(21):5582-5591. [Content Brief]
- [3]. Sun L, et al. Tamsulosin attenuates high glucose- induced injury in glomerular endothelial cells. Bioengineered. 2021 Dec;12(1):5184-5194. [Content Brief]
- [4]. Ida Y, et al. The Selective α1 Antagonist Tamsulosin Alters ECM Distributions and Cellular Metabolic Functions of ARPE 19 Cells in a Concentration-Dependent Manner. Bioengineering (Basel). 2022 Oct 14;9(10):556. [Content Brief]
- [5]. Youm Y H, et al. Apoptosis Induction and Clusterin Expression of NRP-152 Cells by Tamsulosin. Journal of the Korean Continence Society, 2006, 10(2): 132-139.
- [6]. Holanda VAD, et al. Tamsulosin facilitates depressive-like behaviors in mice: Involvement of endogenous glucocorticoids. Brain Res Bull. 2022 Jan;178:29-36. [Content Brief]
- [7]. Kim SE, et al. Effects of Tamsulosin on Urinary Bladder Function and Neuronal Activity in the Voiding Centers of Rats with Cyclophosphamide-induced Overactive Bladder. Int Neurourol J. 2012 Mar;16(1):13-22. [Content Brief]
- [8]. Alabdali H H, et al. Study the anti-inflammatory effects of tamsulosin by the evaluation of inflammatory cells and lung histopathology in an airway inflammation model in rats. Bulletin of Pharmaceutical Sciences. Assiut, 2023, 46(1): 633-645.
